Most interpretation errors in molecular oncology come from collapsing two things into one, seeing an alteration on a report and jumping straight to a drug.
The distance between “an alteration is present” and “this patient should receive this therapy now” is where clinical reasoning lives, and it is the distance where mistakes happen. This page walks that distance deliberately: the chain of questions that converts a single molecular finding into a defensible action, and the points where the chain most often breaks.
The chain: seven questions between mutation and decision
A reported alteration only becomes a treatment decision if it survives every link below. If it fails one, the honest output is not silence, it is a clear statement of why it stopped.
Is the finding technically real?
Before anything clinical, the alteration has to be trustworthy. Low variant allele frequency, low tumor purity, or coverage limits can all produce findings that are artifacts or that under-represent what is truly there. The first question is never “what does it mean?” but “do I believe it?”
Is it a driver or a passenger?
Tumors carry many alterations; only some drive the biology. Clonality and VAF help separate a clonal driver from a subclonal passenger or an emerging resistant clone. Targeting a passenger wastes a line of therapy and exposes the patient to toxicity for no benefit. This link alone reframes a large fraction of “actionable” findings.
Is there a therapy that matches, in this tumor type?
A drug matching the alteration in one cancer does not automatically apply to another. The same alteration can be a strong target in one histology and clinically irrelevant in another.
“Actionable” on a report often means actionable somewhere, not actionable here.
What is the strength of the evidence?
Not all matches are equal. We grade each using established tiering (AMP / ASCO / CAP) so that a well-established, tumor-matched indication is never outranked by a weak, off-label, or purely preclinical rationale. The evidence tier is stated explicitly so the recommendation can be weighed, not just accepted.
Where is the patient in their course?
The same finding leads to different decisions in a treatment-naïve patient versus one who has progressed through multiple lines. Prior therapies, prior response, and current performance status determine whether an option is appropriate now, held in reserve, or no longer relevant. A decision made without this context is a guess.
Is the timing right?
Even a valid, well-matched, well-evidenced option may not belong in the current line. Sequencing matters: using an option too early can forfeit it when it would matter more, and using it too late can mean missing the window entirely. The question is not only “is this a good option?” but “is this the right moment for it?”
What happens after?
A decision that ignores what comes next is incomplete. If a targeted approach is chosen, the likely resistance mechanism and the monitoring plan are part of the decision, not a separate conversation later. Thinking one line ahead is what turns a reaction into a strategy.
Where the chain breaks
Most interpretation errors are not exotic. They are predictable shortcuts:
- “Actionable” read as “approved here.” The single most frequent error, treating a tumor-agnostic or other-tumor finding as if it applied to the patient in front of you.
- A biomarker with no matched drug treated as a treatment. A finding can be biologically interesting and therapeutically empty. Documenting it honestly as “monitor, no current matched therapy” is the correct answer, not a failure.
- Targeting a subclone. Acting on a low-VAF, subclonal alteration as though it were the clonal driver.
- Ignoring co-alterations. A second alteration can blunt or change the implication of the first; reading findings in isolation misses this.
- Off-label without evidence discipline. Reaching for an off-label option without stating its evidence level turns a reasonable idea into an overstatement.
Each of these is the result of jumping a link rather than walking the chain.
Why two experts can still disagree
Even when the chain is followed faithfully, two careful oncologists can reach different conclusions, usually because they weigh the same evidence tier, timing, or sequencing trade-off differently. This is not a flaw; it is the nature of decisions made under uncertainty.
The value of a structured second opinion is that the reasoning is made visible, you can see which link drove the conclusion and judge it for yourself.
The work is the journey
The work of precision oncology is not finding the mutation. Modern sequencing does that reliably.
The work is the disciplined journey from that finding to a decision that fits this patient, this tumor, this moment, and being honest at every link about how strong the ground underneath is.
This content is intended for educational purposes only. It does not constitute individual medical advice and should not replace evaluation by the treating physician.